Genevieve Cardona
Family · Albuquerque, NMNPI 1558799080
Payments from drug & device makers
What this record shows
Almost everything reported here is food and beverage — 100.0% of the total across 269 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. It is spread thinly across 33 manufacturers, the largest accounting for just 13.3% — the pattern of someone who eats at a lot of different presentations. Reporting peaked in 2021 at $1,976 and has fallen 83.2% since, to $331 in 2025. Among family clinicians in NM with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 269 payments — averaging $16.29 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AbbVie$584
- Daiichi Sankyo Inc.$473
- Novo Nordisk$393
- Lilly USA, LLC$299
- Boehringer Ingelheim$284
- AstraZeneca$270
- plus $2K from 27 others
What the payments were for
- Food & beverage$4,382100%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| AbbVie | 51 | $584 |
| Daiichi Sankyo Inc. | 32 | $473 |
| Novo Nordisk | 24 | $393 |
| Lilly USA, LLC | 17 | $299 |
| Boehringer Ingelheim | 16 | $284 |
| AstraZeneca | 17 | $270 |
| Teva Pharmaceuticals USA, Inc. | 10 | $232 |
| Astellas Pharma US Inc | 8 | $174 |
| Pfizer | 11 | $172 |
| Biohaven Pharmaceuticals, Inc. | 8 | $168 |
| Johnson & Johnson | 8 | $150 |
| Exact Sciences | 8 | $144 |
| Merck | 9 | $140 |
| Nestle Healthcare Nutrition Inc. | 7 | $119 |
| Novartis | 6 | $114 |
| Takeda Pharmaceuticals U.S.A., Inc. | 5 | $94 |
| Biohaven Pharmaceutical Holding Company Ltd. | 5 | $92 |
| Organon | 4 | $75 |
| Aimmune Therapeutics, Inc. | 4 | $70 |
| Amarin Pharma, Inc. | 4 | $53 |
| Amgen | 2 | $41 |
| GSK | 2 | $31 |
| Abiomed | 1 | $25 |
| Xeris Pharmaceuticals, Inc. | 1 | $24 |
| Lundbeck LLC | 1 | $21 |
| Vertex | 1 | $21 |
| Corcept Therapeutics | 1 | $20 |
| Nevro Corp. | 1 | $20 |
| Jazz Pharmaceuticals Inc. | 1 | $19 |
| Phathom Pharmaceuticals, Inc. | 1 | $17 |
| Salix Pharmaceuticals, A Division Of Bausch Health US, LLC | 1 | $16 |
| Supernus Pharmaceuticals, Inc. | 1 | $14 |
| Coopersurgical, Inc. | 1 | $13 |
How this compares
$4,382 in reported general payments places this provider in the 95th percentile of 1,080 family providers in New Mexico.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| EliquisApixaban | 17 | $19,796 |
| Basaglar Kwikpen U-100Insulin Glargine,hum.Rec.Anlog | 23 | $11,338 |
| SymbicortBudesonide/Formoterol Fumarate | 20 | $4,746 |
| Levothyroxine Sodium | 275 | $2,770 |
| Atorvastatin Calcium | 219 | $2,443 |
| Rosuvastatin Calcium | 183 | $2,028 |
| Albuterol Sulfate HfaAlbuterol Sulfate | 70 | $2,002 |
| Dextroamphetamine Sulfate ErDextroamphetamine Sulfate | 13 | $1,764 |
| Lisinopril | 179 | $1,736 |
| SynthroidLevothyroxine Sodium | 36 | $1,388 |
| Gabapentin | 79 | $1,346 |
| Fluticasone-SalmeterolFluticasone Propion/Salmeterol | 11 | $1,255 |
| Escitalopram Oxalate | 64 | $1,123 |
| Tamsulosin Hcl | 66 | $1,092 |
| Baclofen | 81 | $1,016 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| PfizerEliquis | $172 | $19,79617 claims |
| AstraZenecaSymbicort | $270 | $4,74620 claims |
| AbbVieSynthroid | $584 | $1,38836 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 1,080 family providers in New Mexico.
Other family in Albuquerque
- Barbara FranklinAlbuquerque$28K
- Melanie DuranAlbuquerque$15K
- Irasema LlewellynAlbuquerque$14K
- Charles GallegosAlbuquerque$10K
- Marlyn NewbyAlbuquerque$9K
- Annmarie FoleyAlbuquerque$8K
- Aimee CasarezAlbuquerque$7K
- Rita SuharliAlbuquerque$6K
- Matthew TotterAlbuquerque$6K
- Roberta ChampouillonAlbuquerque$6K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.